IP Library Granted Patent US 8,927,595
Granted Patent B2
US 8,927,595 · App. 13/116,547 · Granted Jan 6, 2015

Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,595
App. No.
13/116,547
Granted
Jan 6, 2015
Kind
B2
Abstract

An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.

Claims (53)

1. A method for the treatment or prophylaxis of lice infestation, the method comprising steps of:

a) applying topically to a surface area of a host who is suffering from or susceptible to infestation with lice a formulation comprising:

an effective amount of dissolved ivermectin;

about 20% to about 35% by weight olive oil;

about 1% to about 5% by weight shea butter;

nonionic surfactants comprising oleyl alcohol, sorbitan tristearate, and lanolin alcohol;

a solubilizing agent comprising cetyl acetate, polysorbate 80, and acetylated lanolin alcohol;

about 0.01% to about 2% by weight methylparaben;

about 0.01% to about 0.5% by weight propylparaben;

about 1% to about 5% by weight of a conditioner comprising cyclomethicone; and

about 30% to about 40% by weight water; and

b) maintaining the composition in contact with the surface area for a period of time that is from about 1 to about 60 minutes in length.

2. The method of claim 1 , further comprising a step of:

c) washing the area with water.

3. The method of claim 1 , wherein the lice are head lice and the surface area comprises head hair of the host.

4. The method of claim 1 , wherein the lice are body lice and the surface area comprises a body area of the host.

5. The method of claim 1 , wherein the lice are pubic lice and the surface area comprises a pubic area, facial hair, eyelashes, eyebrows, armpits, chest hair, or scalp of the host.

6. The method of claim 1 , wherein the lice are resistant to one or more of pyrethrin, permethrin and malathion.

7. The method of claim 1 , wherein the step of applying comprises applying to a host who has previously used one or more of a pyrethrin, permethrin and malathion containing formulation.

8. The method of claim 1 , wherein the lice are susceptible to ivermectin.

9. The method of claim 1 , wherein the step of applying comprises applying to a host who has not previously used one or more of a pyrethrin, permethrin and malathion containing formulation.

10. The method of claim 1 , wherein the period of time is from about 3 minutes to about 60 minutes in length.

11. The method of claim 1 , wherein the period of time is about 3 minutes in length.

12. The method of claim 1 , wherein the period of time is about 5 minutes in length.

13. The method of claim 1 , wherein the period of time is about 10 minutes in length.

14. The method of claim 1 , wherein the formulation is in the form of a lotion.

15. The method of claim 1 , wherein the step of applying comprises applying a unit dose of about 1 ml to about 100 ml of the formulation.

16. The method of claim 1 , wherein the step of applying comprises applying a unit dose of about 3 ml to about 75 ml of the formulation.

17. The method of claim 15 or 16 , wherein the unit dose comprises from about 0.1% to about 2.0% w/v ivermectin.

18. The method of claim 15 or 16 , wherein the unit dose comprises about 0.5% w/v ivermectin.

19. The method of claim 1 , wherein the formulation does not include any glycols.

20. The method of claim 1 , wherein the formulation comprises below 5% by weight of a glycol.

21. The method of claim 1 , wherein the olive oil is present in an amount of about 27.5% by weight of the formulation.

22. The method of claim 1 , wherein the ivermectin is present in an amount of about 0.25% to about 1% by weight of the formulation.

23. The method of claim 1 , wherein the formulation is formulated as a cream, gel, pomade, shampoo-conditioner, cream rinse or lotion.

24. The method of claim 23 , wherein the formulation is formulated as a cream.

25. The method of claim 1 , wherein the formulation is indirectly ovicidal.

26. The method of claim 1 , wherein the formulation has a volume of about 1 mL to about 100 mL and contains a unit dose of ivermectin.

27. The method of claim 1 , wherein the formulation comprises oleyl alcohol and lanolin alcohol with a combined concentration of about 10% to about 35% by weight.

28. The method of claim 1 , wherein the formulation comprises oleyl alcohol and lanolin alcohol with a combined concentration of about 18% to about 24% by weight.

29. The method of claim 1 , wherein the formulation comprises about 5% to about 15% by weight oleyl alcohol.

30. The method of claim 1 , wherein the formulation comprises about 3% to about 15% by weight lanolin alcohol.

31. The method of claim 1 , wherein the formulation comprises about 5% to about 10% by weight lanolin alcohol.

32. The method of claim 1 , wherein the formulation comprises about 0.1% to about 3% by weight sorbitan tristearate.

33. The method of claim 1 , wherein the formulation comprises about 0.5% to about 10% by weight cetyl acetate.

34. The method of claim 1 , wherein the formulation comprises about 1% to about 4% by weight cetyl acetate.

35. The method of claim 1 , wherein the formulation comprises about 5% to about 25% by weight polysorbate 80.

36. The method of claim 1 , wherein the formulation comprises about 10% to about 15% by weight polysorbate 80.

37. The method of claim 1 , wherein the formulation comprises about 0.10% to about 3% by weight acetylated lanolin alcohol.

38. The method of claim 1 , wherein the formulation comprises about 0.5% to about 1% by weight acetylated lanolin alcohol.

39. The method of claim 1 , wherein the ivermectin is present in an amount of about 0.05% to about 5% by weight of the formulation.

40. The method of claim 1 , wherein the olive oil is present in an amount of about 20% to about 30% by weight of the formulation.

41. The method of claim 1 , wherein the olive oil is present in an amount of about 25% to about 28% by weight of the formulation.

Assignments (11)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
SECURITY INTEREST Recorded Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057346/0837 →
SECURITY INTEREST Recorded Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: SANOFI-TOPAZ INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 037190/0575 →
SECURITY INTEREST Recorded Nov 11, 2015
From: ARBOR PHARMACEUTICALS, LLC
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS AGENT
Reel/Frame 037013/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2013
From: SPRING, NICHOLAS; GWOZDZ, GARRY T.
To: TOPAZ PHARMACEUTICALS LLC
Reel/Frame 031024/0177 →
MERGER Recorded Aug 16, 2013
From: TOPAZ PHARMACEUTICALS INC.
To: SANOFI - TOPAZ, INC.
Reel/Frame 031024/0620 →
CHANGE OF NAME Recorded Aug 16, 2013
From: TOPAZ PHARMACEUTICALS LLC
To: TOPAZ PHARMACEUTICALS INC.
Reel/Frame 031031/0071 →